Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 6:00AM CST

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update GlobeNewswire - Wed Nov 5, 6:00AM CST

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population  Selective CBP...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 6:30AM CST

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs GlobeNewswire - Thu Oct 30, 6:30AM CDT

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors  ...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit GlobeNewswire - Thu Oct 16, 6:00AM CDT

CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire - Wed Aug 27, 6:00AM CDT

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update GlobeNewswire - Tue Aug 5, 6:00AM CDT

FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track ...

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire - Thu May 22, 6:00AM CDT

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update GlobeNewswire - Wed May 14, 6:00AM CDT

FHTX : 4.36 (-4.80%)
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference GlobeNewswire - Mon May 5, 6:00AM CDT

FHTX : 4.36 (-4.80%)

Barchart Exclusives

As Nike Shakes Up Its C-Suite, Should You Buy, Sell, or Hold NKE Stock? Barchart - 30 minutes ago
Nike’s sweeping C-suite overhaul under its “Win Now” plan signals a bold reset. So, is the stock a buy, sell, or hold? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot